To this regard, radiolabeled prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is emerging as a very useful imaging method for detecting tumor lesions in BRPCa patients, with higher DR compared to other imaging modalities [1,2,3,4,5]. The gene discussed is FOLH1; the disease is neoplasm.